Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +50 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603874 |
| 2 | ▲2 | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603875 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603876 |
| 4 | ▲1 | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603878 |
| 4 | ▲2 | Malignant Pancreatic Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603877 |
| 6 | ▲2 | Malignant Vulvar Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603879 |
| 7 | ▲3 | Malignant Kidney Neoplasm | +6.6 | 80 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603880 |
| 8 | ▲4 | Malignant Esophageal Neoplasm | +3.4 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603881 |
| 9 | ▲5 | Malignant Anal Neoplasm | +3.4 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603882 |
| 10 | ▲4 | Malignant Salivary Gland Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603883 |
| 11 | ▲3 | Malignant Testicular Neoplasm | +3.3 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603884 |
| 11 | ▲2 | Malignant Vaginal Neoplasm | +3.3 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603885 |
| 13 | ▼2 | Malignant Mesothelioma | +3.3 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603886 |
| 14 | = | Malignant Liver Neoplasm | 0 | 56.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603888 |
| 14 | = | Malignant Lung Neoplasm | 0 | 56.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603887 |
| 14 | = | Malignant Prostate Neoplasm | 0 | 56.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603889 |
| 14 | = | Malignant Rectal Neoplasm | 0 | 56.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603890 |
| 18 | ▲14 | Malignant Thyroid Gland Neoplasm | -3.3 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603891 |
| 19 | ▲5 | Malignant Hypopharyngeal Neoplasm | -3.3 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603892 |
| 20 | ▲2 | Malignant Breast Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603893 |
| 20 | ▲3 | Malignant Central Nervous System Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603894 |
| 22 | ▲4 | Malignant Penile Neoplasm | -6.7 | 30 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603895 |
| 23 | ▲3 | Leukemia | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603896 |
| 23 | ▲5 | Malignant Ovarian Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603897 |
| 23 | ▲6 | Malignant Uterine Corpus Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603898 |
| 26 | ▲4 | Malignant Gastric Neoplasm | -13.4 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603899 |
| 27 | ▲4 | Multiple Myeloma | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603900 |
| 27 | ▲5 | Non-Hodgkin Lymphoma | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603901 |
| 29 | ▲5 | Malignant Cervical Neoplasm | -20 | 6.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603902 |
| 30 | ▲5 | Hodgkin Lymphoma | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603903 |
| 31 | ▲5 | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2603904 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 232565d9173bda1706a3b9ed